<SEC-DOCUMENT>0001104659-21-086498.txt : 20210629
<SEC-HEADER>0001104659-21-086498.hdr.sgml : 20210629
<ACCEPTANCE-DATETIME>20210629070635
ACCESSION NUMBER:		0001104659-21-086498
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210629
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210629
DATE AS OF CHANGE:		20210629

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Synthetic Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12584
		FILM NUMBER:		211055566

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SHEFFIELD PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19970730
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2120759d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to Section 13 or 15(d)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of the Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Date of Report (Date of earliest event reported):&nbsp;June
29, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SYNTHETIC BIOLOGICS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Nevada</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-12584</B></FONT></TD>
    <TD STYLE="width: 1%; padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13-3808303</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File No.)</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>9605 Medical Center Drive, Suite 270</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rockville, MD 20850</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices and zip
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(301) 417-4364</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section 12(b)
of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; border: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 34%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="white-space: nowrap; width: 33%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-left: 6.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, par value $0.001 per share</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYN</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NYSE American</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2 of this chapter).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">Emerging
growth company&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&uml;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item&nbsp;7.01
Regulation FD Disclosure.</B></FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 29, 2021, Synthetic
Biologics, Inc. (the &ldquo;Company&rdquo;) issued a press release announcing that <FONT STYLE="color: windowtext">that patient dosing
and observation has been completed in its Phase 1, open label, single-ascending dose (SAD) clinical trial of SYN-020 intestinal alkaline
phosphatase (IAP). The Phase 1 SAD study enrolled 24 healthy adult volunteers into four cohorts with SYN-020 given orally as single doses
ranging from 5 mg to 150 mg daily. Analyses of preliminary data demonstrated that SYN-020 maintained a favorable safety profile, was well
tolerated at all dose levels and no adverse events were attributed to the study drug. No serious adverse events were reported</FONT>.
<FONT STYLE="color: windowtext">A second Phase 1 clinical trial intended to evaluate the safety, tolerability and biodistribution of multiple-ascending
doses (MAD) of SYN-020 in healthy volunteers is expected to commence during the third quarter of 2021. Topline results from this clinical
trial are anticipated during the second quarter of 2022. Both Phase 1 SAD and MAD studies are intended to support the development of SYN-020
in multiple potential clinical indications, including celiac disease, nonalcoholic fatty liver disease, radiation enteropathy, and indications
to treat and prevent metabolic and inflammatory disorders associated with aging, which are supported by the Company&rsquo;s collaboration
with Massachusetts General Hospital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A copy of the press release
is furnished as Exhibit 99.1 to this Report on Form 8-K. The information contained in the press release is being furnished to the Securities
and Exchange Commission (the &ldquo;Commission&rdquo;) and shall not be deemed incorporated by reference into any of the Registrant&rsquo;s
registration statements or other filings with the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in this Item
7.01, and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be &ldquo;filed&rdquo;
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section
or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with
the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general
incorporation language in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8.01 Other Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 29, 2021, the Company
announced that <FONT STYLE="color: windowtext">that patient dosing and observation has been completed in its Phase 1, open label, SAD
clinical trial of SYN-020 intestinal alkaline phosphatase (IAP). The Phase 1 SAD study enrolled 24 healthy adult volunteers into four
cohorts with SYN-020 given orally as single doses ranging from 5 mg to 150 mg daily. Analyses of preliminary data demonstrated that SYN-020
maintained a favorable safety profile, was well tolerated at all dose levels and no adverse events were attributed to the study drug.
No serious adverse events were reported</FONT>. <FONT STYLE="color: windowtext">A second Phase 1 clinical trial intended to evaluate the
safety, tolerability and biodistribution of multiple-ascending doses of SYN-020 in healthy volunteers is expected to commence during the
third quarter of 2021. Topline results from this clinical trial are anticipated during the second quarter of 2022. Both Phase 1 SAD and
MAD studies are intended to support the development of SYN-020 in multiple potential clinical indications, including celiac disease, nonalcoholic
fatty liver disease, radiation enteropathy, and indications to treat and prevent metabolic and inflammatory disorders associated with
aging, which are supported by the Company&rsquo;s collaboration with Massachusetts General Hospital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01. Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(d) Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following exhibit is furnished with this Current
Report on Form 8-K:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; padding-bottom: 1pt; width: 10%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="padding-bottom: 1pt; width: 1%; padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 89%; padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt"><A HREF="tm2120759d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 0.8pt; text-align: justify"><A HREF="tm2120759d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press
    Release issued by Synthetic Biologics, Inc., dated June 29, 2021.</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: June 29, 2021</P></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: 2.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYNTHETIC BIOLOGICS, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt; width: 50%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 3%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 5%">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt; width: 42%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid; padding-right: 1.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Steven A. Shallcross</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt">&nbsp;</TD>
    <TD STYLE="padding-right: 0.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">Chief Executive Officer</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.8pt 0pt 0">and Chief Financial Officer</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2120759d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="tm2120759d1_ex99-1img001.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>Synthetic Biologics Provides
Update on SYN-020 Intestinal Alkaline Phosphatase </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>Phase 1 Single-Ascending
Dose Clinical Trial</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B><I>Orally Administered SYN-020
Observed to be Well Tolerated in Healthy Volunteers; A Second Phase 1 Multiple-Ascending Dose Study is on Track to Begin in Q3 2021</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Immediate Release</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext"><B>Rockville,
MD, June 29, 2021 &ndash;</B></FONT> <U>Synthetic Biologics, Inc.</U> <FONT STYLE="color: windowtext">(NYSE American: SYN),</FONT> a
diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI)
diseases in areas of high unmet need, <FONT STYLE="color: windowtext">today announced that patient dosing and observation has been completed
in its Phase 1, open label, single-ascending dose (SAD) clinical trial of SYN-020 intestinal alkaline phosphatase (IAP). The Phase 1
SAD study enrolled 24 healthy adult volunteers into four cohorts with SYN-020 given orally as single doses ranging from 5 mg to 150 mg
daily. Analyses of preliminary data demonstrated that SYN-020 maintained a favorable safety profile, was well tolerated at all dose levels,
and no adverse events were attributed to the study drug. No serious adverse events were reported. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A second Phase 1 clinical trial intended to evaluate
the safety, tolerability and biodistribution of multiple-ascending doses (MAD) of SYN-020 in healthy volunteers is expected to commence
during the third quarter of 2021. Topline results from this clinical trial are anticipated during the second quarter of 2022. Both Phase
1 SAD and MAD studies are intended to support the development of SYN-020 in multiple potential clinical indications, including celiac
disease, nonalcoholic fatty liver disease (NAFLD), radiation enteropathy, and indications to treat and prevent metabolic and inflammatory
disorders associated with aging, which are supported by the Company&rsquo;s collaboration with Massachusetts General Hospital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;SYN-020 is a promising, versatile program
that has the potential to become a multi-indication, platform therapeutic capable of addressing a considerable unmet need for innovative
new therapies targeting disorders stemming from gastrointestinal (GI) inflammation, including celiac disease, NAFLD, and age-related metabolic
and inflammatory diseases,&rdquo; said Steven A. Shallcross, Chief Executive Officer of Synthetic Biologics. &ldquo;U.S. cases of celiac
disease are expected to surpass 4.3 million by 2023, representing a significant market opportunity for a highly differentiated product
such as SYN-020. We are very encouraged by these positive Phase 1 results and look forward to SYN-020&rsquo;s continued development, which
includes the planned initiation of a second Phase 1, multiple-ascending dose study during the third quarter of 2021.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="color: windowtext">SYN-020 </FONT>is
a recombinant bovine IAP formulated for oral delivery to the small intestine and designed to diminish intestinal inflammation, tighten
the gut barrier to diminish &ldquo;leaky gut,&rdquo; and promote a healthy microbiome. Despite its broad therapeutic potential, a key
hurdle to commercialization has been the high cost of IAP manufacture. Synthetic Biologics has overcome this hurdle and has the ability
to produce SYN-020 at a scale and cost viable for clinical and commercial development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Synthetic Biologics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (NYSE American:
SYN) is a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat
gastrointestinal (GI) diseases in areas of high unmet need. The Company&rsquo;s lead candidates are: (1) SYN-004 (ribaxamase) which
is designed to degrade certain commonly used intravenous (IV) beta-lactam antibiotics within the gastrointestinal (GI) tract to
prevent (a) microbiome damage, (b) <I>Clostridioides difficile</I> infection (CDI), (c) overgrowth of pathogenic organisms, (d) the
emergence of antimicrobial resistance (AMR), and (e) acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell
transplant (HCT) recipients, and (2) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP)
produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit
Synthetic Biologics' website at <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>www.syntheticbiologics.com</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This release contains forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified
by terminology such as &quot;may,&quot; &quot;should,&quot; &quot;potential,&quot; &quot;continue,&quot; &quot;expects,&quot; &quot;anticipates,&quot;
 &quot;intends,&quot; &quot;plans,&quot; &quot;believes,&quot; &quot;estimates,&quot; and similar expressions, and includes statements
regarding <FONT STYLE="color: windowtext">commencing</FONT> a <FONT STYLE="color: windowtext">second Phase 1 clinical trial intended to
evaluate the safety, tolerability and biodistribution of multiple-ascending doses (MAD) of SYN-020 in healthy volunteers during the third
quarter of 2021, announcing topline results from the second Phase 1 clinical trial during the second quarter of 2022, the Phase 1 SAD
and MAD studies supporting the development of SYN-020 in multiple potential clinical indications, including celiac disease, nonalcoholic
fatty liver disease (NAFLD), radiation enteropathy, and indications to treat and prevent metabolic and inflammatory disorders associated
with aging</FONT></I><FONT STYLE="color: windowtext">, <I>SYN-020 having the potential to become a multi-indication, platform therapeutic
capable of addressing a considerable unmet need for innovative new therapies targeting disorders stemming from gastrointestinal (GI) inflammation,
including celiac disease, NAFLD, and age-related metabolic and inflammatory diseases</I></FONT><I>, the expected increase in the number
of cases of celiac disease in the U.S and the intended benefits to be derived from SYN-004 and SYN-020. These forward-looking statements
are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties,
many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions
from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially
from current expectations include, among others, Synthetic Biologics' ability to develop SYN-020 in multiple indications, the ability
to commence a multiple-ascending dose study of SYN-020 during the third quarter of 2021 and the announcement of topline data during the
second quarter of 2022, the ability to continue to comply with continued listing requirements of the NYSE American, the ability of its
product candidates to demonstrate safety and effectiveness, as well as results that are consistent with prior results, Synthetic Biologics'
clinical trials continuing and/or beginning enrollment as expected, a failure to receive the necessary regulatory approvals for commencement
of clinical trials and commercialization of Synthetic Biologics' therapeutics, including approval of proposed trial designs, a failure
of Synthetic Biologics' clinical trials, and those conducted by investigators, for SYN-004 and SYN-020 to be commenced or completed on
time or to achieve desired results and benefits, a failure of Synthetic Biologics' clinical trials to continue enrollment as expected
or receive anticipated funding, a failure of Synthetic Biologics to successfully develop, market or sell its products, Synthetic Biologics'
inability to maintain its material licensing agreements, or a failure by Synthetic Biologics or its strategic partners to successfully
commercialize products, Synthetic Biologics&rsquo; ability to achieve acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of Synthetic Biologics' products by competitors that render Synthetic Biologics' products obsolete
or non-competitive, the continued maintenance and growth of Synthetic Biologics' patent estate, Synthetic Biologics becoming and remaining
profitable, Synthetic Biologics' ability to obtain or maintain the capital or grants necessary to fund its research and development activities,
a loss of any of Synthetic Biologics' key scientists or management personnel and other factors described in Synthetic Biologics' Form
10-K for the year ended December 31, 2020 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and
8-K. The information in this release is provided only as of the date of this release, and Synthetic Biologics undertakes no obligation
to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except
as required by law.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Synthetic Biologics, Inc. (Corporate and Investors)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vincent I. Perrone, Director Corporate Communication, (240) 660-2000,
<U>info@syntheticbiologics.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ogilvy (Media)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Gregory Kelley, Senior Vice President, (404) 836-2302, <U>gregory.kelley@ogilvy.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"># # #</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2120759d1_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2120759d1_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !> 0$# 2(  A$! Q$!_\0
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MG<SO;(S,?4DCFFV$FB6LSZ?I[6$,FXE[>WV*2>^5'?BG[1*P*G*5VCR?P_\
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MV!QC^1IXW+:-&ASPW7XDX''UJU?DDM'^!RNZN[\$ZB9[*6R=B6@.Y,_W3V_
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MZ2^;&"$+RE@H((P >W-.I3DYJ2_K6Y%"O3A1E"5[N^WFK=_\R#QQ_P B=?\
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AS+%S7*ZC$5%1 B*%51@ #  I:**Z#B"BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
